PF 5402536
Alternative Names: NIC7-001; PF-05402536; PF-5402536Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Pfizer
- Class Smoking cessation therapies; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Smoking withdrawal
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Smoking-withdrawal in Canada (IM)
- 01 Dec 2015 Pfizer completes a phase I trial in Smoking withdrawal in Canada (NCT01672645)
- 09 Aug 2012 Phase-I clinical trials in Smoking withdrawal in Canada (IM)